Structural insights into the substrate-binding site of main protease for the structure-based COVID-19 drug discovery.
COVID-19
crystallographic waters
docking simulations
drug design
hot-spot residues
main protease
structural analysis
Journal
Proteins
ISSN: 1097-0134
Titre abrégé: Proteins
Pays: United States
ID NLM: 8700181
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
30
01
2022
received:
19
11
2021
accepted:
31
01
2022
pubmed:
5
2
2022
medline:
14
4
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
An attractive drug target to combat COVID-19 is the main protease (M
Substances chimiques
Ligands
0
Protease Inhibitors
0
Water
059QF0KO0R
Endopeptidases
EC 3.4.-
Peptide Hydrolases
EC 3.4.-
3C-like proteinase, SARS-CoV-2
EC 3.4.22.-
Coronavirus 3C Proteases
EC 3.4.22.28
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1090-1101Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289-293. doi:10.1038/s41586-020-2223-y
Dai W, Zhang B, Jiang X, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331-1335. doi:10.1126/science.abb4489
Kneller DW, Galanie S, Phillips G, O'Neill HM, Coates L, Kovalevsky A. Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals. Structure. 2020;28:1313-1320. doi:10.1016/j.str.2020.10.007
Li Z, Li X, Huang Y, et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc Natl Acad Sci USA. 2020;117:27381-27387. doi:10.1073/pnas.2010470117
Kumar K, Lupoli TJ. Exploiting existing molecular scaffolds for long-term COVID treatment. ACS Med Chem Lett. 2020;11:1357-1360. doi:10.1021/acsmedchemlett.0c00254
Świderek K, Moliner V. Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro by QM/MM computational methods. Chem Sci. 2020;11:10626-10630. doi:10.1039/d0sc02823a
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21:730-738. doi:10.1002/cbic.202000047
Francés-Monerris A, Hognon C, Miclot T, et al. Molecular basis of SARS-CoV-2 infection and rational design of potential antiviral agents: modeling and simulation approaches. J Proteome Res. 2020;19:4291-4315. doi:10.1021/acs.jproteome.0c00779
Su H, Zhou F, Huang Z, et al. Molecular insights into small-molecule drug discovery for SARS-CoV-2. Angew Chem Int Ed. 2021;60:9789-9802. doi:10.1002/anie.202008835
Muratov EN, Amaro R, Andrade CH, et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev. 2021;50:9121-9151. doi:10.1039/d0cs01065k
Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409-412. doi:10.1126/science.abb3405
Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6:315-331. doi:10.1021/acscentsci.0c00272
Cho E, Rosa M, Anjum R, et al. Dynamic profiling of β-coronavirus 3CL Mpro protease ligand-binding sites. J Chem Inf Model. 2021;61:3058-3073. doi:10.1021/acs.jcim.1c00449
Kneller DW, Phillips G, O'Neill HM, et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020;11:3202. doi:10.1038/s41467-020-16954-7
Howes L. Targeting a coronavirus protease. C&EN. 2020;98:5. doi:10.1021/cen-09812-scicon1
Nguyen DD, Gao K, Chen J, Wang R, Wei G. Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. Chem Sci. 2020;11:12036-12046. doi:10.1039/d0sc04641h
Panda PK, Arul MN, Patel P, et al. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2. Sci Adv. 2020;6:eabb8097. doi:10.1126/sciadv.abb8097
Inizan TJ, Célerse F, Adjoua O, et al. High-resolution mining of the SARS-CoV-2 main protease conformational space: supercomputer-driven unsupervised adaptive sampling. Chem Sci. 2021;12:4889-4907. doi:10.1039/d1sc00145k
Goyal B, Goyal D. Targeting the dimerization of the Main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb Sci. 2020;22:297-305. doi:10.1021/acscombsci.0c00058
Akaji K, Konno H. Design and evaluation of anti-SARS-coronavirus agents based on molecular interactions with the viral protease. Molecules. 2020;25:3920. doi:10.3390/molecules25173920
Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11:5047. doi:10.1038/s41467-020-18709-w
Ghahremanpour MM, Tirado-Rives J, Deshmukh M, et al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett. 2020;11:2526-2533. doi:10.1021/acsmedchemlett.0c00521
Cross TJ, Takahashi GR, Diessner EM, et al. Sequence characterization and molecular modeling of clinically relevant variants of the SARS-CoV-2 main protease. Biochemistry. 2020;59:3741-3756. doi:10.1021/acs.biochem.0c00462
Suárez D, Díaz N. SARS-CoV-2 Main protease: a molecular dynamics study. J Chem Inf Model. 2020;60:5815-5831. doi:10.1021/acs.jcim.0c00575
Achutha AS, Pushpa VL, Suchitra S. Theoretical insights into the anti-SARS-CoV-2 activity of chloroquine and its analogs and in silico screening of main protease inhibitors. J Proteome Res. 2020;19:4706-4717. doi:10.1021/acs.jproteome.0c00683
Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678-692. doi:10.1038/s41422-020-0356-z
Acharya A, Agarwal R, Baker MB, et al. Supercomputer-based ensemble docking drug discovery pipeline with application to Covid-19. J Chem Inf Model. 2020;60:5832-5852. doi:10.1021/acs.jcim.0c01010
Pavlova A, Lynch DL, Daidone I, et al. Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease. Chem Sci. 2021;12:1513-1527. doi:10.1039/d0sc04942e
Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv. 2020;6:eabe0751. doi:10.1126/sciadv.abe0751
Jan J, Cheng TR, Juang Y, et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2021;118:e2021579118. doi:10.1073/pnas.2021579118
Gao J, Zhang L, Liu X, et al. Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2. J Phys Chem Lett. 2020;11:7267-7272. doi:10.1021/acs.jpclett.0c01894
Rathnayake AD, Zheng J, Kim Y, et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci Transl Med. 2020;12:eabc5332. doi:10.1126/scitranslmed.abc5332
Ngo ST, Nguyen HM, Huong LTT, et al. Assessing potential inhibitors of SARS-CoV-2 main protease from available drugs using free energy perturbation simulations. RSC Adv. 2020;10:40284-40290. doi:10.1039/D0RA07352K
Zhang S, Krumberger M, Morris MA, et al. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: a tutorial for students and scientists. Eur J Med Chem. 2021;218:113390. doi:10.1016/j.ejmech.2021.113390
Mengist HM, Fan X, Jin T. Designing of improved drugs for COVID-19: crystal structure of SARS-CoV-2 main protease Mpro. Signal Transduct Target Ther. 2020;5:67-68. doi:10.1038/s41392-020-0178-y
Bárcena M, Barnes CO, Beck M, et al. Structural biology in the fight against COVID-19. Nat Struct Mol Biol. 2021;28:2-7. doi:10.1038/s41594-020-00544-8
Gysi DM, Valle I, Zitnik M, et al. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci USA. 2021;118:e2025581118. doi:10.1073/pnas.2025581118
Sepay N, Saha PC, Shahzadi Z, Chakraborty A, Halder UC. A crystallography-based investigation of weak interactions for drug design against COVID-19. Phys Chem Chem Phys. 2021;23:7261-7270. doi:10.1039/d0cp05714b
Kneller DW, Phillips G, Weiss KL, Zhang Q, Coates L, Kovalevsky A. Direct observation of protonation state modulation in SARS-CoV-2 main protease upon inhibitor binding with neutron crystallography. J Med Chem. 2021;64:4991-5000. doi:10.1021/acs.jmedchem.1c00058
Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28:235-242. doi:10.1093/nar/28.1.235
Hatada R, Okuwaki K, Mochizuki Y, et al. Fragment molecular orbital based interaction analyses on COVID-19 Main protease-inhibitor N3 complex (PDB ID: 6LU7). J Chem Inf Model. 2020;60:3593-3602. doi:10.1021/acs.jcim.0c00283
Tanaka S, Tokutomi S, Hatada R, et al. Dynamic cooperativity of ligand-residue interactions evaluated with the fragment molecular orbital method. J Phys Chem B. 2021;125:6501-6512. doi:10.1021/acs.jpcb.1c03043
Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60:3277-3286. doi:10.1021/acs.jcim.0c00179
Huynh T, Wang H, Luan B. In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's Main protease. J Phys Chem Lett. 2020;11:4413-4420. doi:10.1021/acs.jpclett.0c00994
Maffucci I, Contini A. In silico drug repurposing for SARS-CoV-2 Main proteinase and spike proteins. J Proteome Res. 2020;19:4637-4648. doi:10.1021/acs.jproteome.0c00383
Vatansever EC, Yang KS, Drelich AK, et al. Bepridil is potent against SARS-CoV-2 in vitro. Proc Natl Acad Sci USA. 2021;118:e2012201118. doi:10.1073/pnas.2012201118
Deeks HM, Walters RK, Barnoud J, Glowacki DR, Mulholland AJ. Interactive molecular dynamics in virtual reality is an effective tool for flexible substrate and inhibitor docking to the SARS-CoV-2 Main protease. J Chem Inf Model. 2020;60:5803-5814. doi:10.1021/acs.jcim.0c01030
Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A. Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design. Int J Mol Sci. 2020;21:3099. doi:10.3390/ijms21093099
Gahlawat A, Kumar N, Kumar R, et al. Structure-based virtual screening to discover potential Lead molecules for the SARS-CoV-2 Main protease. J Chem Inf Model. 2020;60:5781-5793. doi:10.1021/acs.jcim.0c00546
Arafet K, Serrano-Aparicio N, Lodola A, et al. Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Chem Sci. 2021;12:1433-1444. doi:10.1039/d0sc06195f
Bagheri S, Behnejad H, Firouzi R, Karimi-Jafari MH. Using the semiempirical quantum mechanics in improving the molecular docking: a case study with CDK2. Mol Inf. 2020;39:2000036. doi:10.1002/minf.202000036
Krzywinski M, Altman N. Principal component analysis, Jake Lever. Nat Methods. 2017;14:641-642. doi:10.1038/nmeth.4346
Giuliani A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov Today. 2017;22:1069-1076. doi:10.1016/j.drudis.2017.01.005
Kalgin IV, Caflisch A, Chekmarev SF, Karplus M. New insights into the folding of a β-Sheet Miniprotein in a reduced space of collective hydrogen bond variables: application to a hydrodynamic analysis of the folding flow. J Phys Chem B. 2013;117:6092-6105. doi:10.1021/jp401742y
Salehi N, Amininasab M, Firouzi R, Karimi-Jafari MH. Efficient construction of a diverse conformational library for amyloid-β as an intrinsically disordered protein. J Mol Graph Model. 2019;88:183-193. doi:10.1016/j.jmgm.2019.01.009
Mondal D, Warshel A. Exploring the mechanism of covalent inhibition: simulating the binding free energy of α-Ketoamide inhibitors of the Main protease of SARS-CoV-2. Biochemistry. 2020;59:4601-4608. doi:10.1021/acs.biochem.0c00782
Zanetti-Polzi L, Smith MD, Chipot C, et al. Tuning proton transfer thermodynamics in SARS-CoV-2 main protease: implications for catalysis and inhibitor design. J Phys Chem Lett. 2021;12:4195-4202. doi:10.1021/acs.jpclett.1c00425
Feng Z, Chen M, Xue Y, et al. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Brief Bioinform. 2021;22:946-962. doi:10.1093/bib/bbaa260
Naveja JJ, Madariaga-Mazón A, Flores-Murrieta F, et al. Union is strength: antiviral and anti-inflammatory drugs for COVID-19. Drug Discov Today. 2021;26:229-239. doi:10.1016/j.drudis.2020.10.018
Ngo ST, Tam NM, Pham MQ, Nguyen TH. Benchmark of popular free energy approaches revealing the inhibitors binding to SARS-CoV-2 Mpro. J Chem Inf Model. 2021;61:2302-2312. doi:10.1021/acs.jcim.1c00159
Kumar S, Sharma PP, Shankar U, et al. Discovery of new Hydroxyethylamine analogs against 3CLpro protein target of SARS-CoV-2: molecular docking, molecular dynamics simulation, and structure-activity relationship studies. J Chem Inf Model. 2020;60:5754-5770. doi:10.1021/acs.jcim.0c00326
Gao K, Nguyen DD, Chen J, Wang R, Wei G. Repositioning of 8565 existing drugs for COVID-19. J Phys Chem Lett. 2020;11:5373-5382. doi:10.1021/acs.jpclett.0c01579
Manandhar A, Blass BE, Colussi DJ, et al. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a inhibitors: in silico modeling and in vitro screening. J Chem Inf Model. 2021;61:1020-1032. doi:10.1021/acs.jcim.0c01457
Banerjee R, Perera L, Tillekeratne LMV. Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today. 2021;26:804-816. doi:10.1016/j.drudis.2020.12.005
Yuce M, Cicek E, Inan T, Dag AB, Kurkcuoglu O, Sungur FA. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins. 2021;89:1425-1441. doi:10.1002/prot.26164
Zev S, Raz K, Schwartz R, Tarabeh R, Gupta PK, Major DT. Benchmarking the ability of common docking programs to correctly reproduce and score binding modes in SARS-CoV-2 protease Mpro. J Chem Inf Model. 2021;61:2957-2966. doi:10.1021/acs.jcim.1c00263
Ramos-Guzmán CA, Ruiz-Pernía JJ, Tuñón I. A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design. Chem Sci. 2021;12:3489-3496. doi:10.1039/d0sc04978f
Murtagh F, Contreras P. Algorithms for hierarchical clustering: an overview. WIREs Data Mining Knowl Discov. 2017;7:e1219. doi:10.1002/widm.1219
Altman N, Krzywinski M. Clustering. Nat Methods. 2017;14:545-546. doi:10.1038/nmeth.4299
Chen S, Jonas F, Shen C, Higenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein Cell. 2010;1:59-74. doi:10.1007/s13238-010-0011-4
Noske GD, Nakamura AM, Gawriljuk VO, et al. A crystallographic snapshot of SARS-CoV-2 Main protease maturation process. J Mol Bio. 2021;433:167118. doi:10.1101/2020.12.23.424149
Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol. 1999;285:1735-1747. doi:10.1006/jmbi.1998.2401
Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781-1802. doi:10.1002/jcc.20289
Westbrook JD, Shao C, Feng Z, Zhuravleva M, Velankar S, Young J. The chemical component dictionary: complete descriptions of constituent molecules in experimentally determined 3D macromolecules in the protein data Bank. Bioinformatics. 2015;31:1274-1278. doi:10.1093/bioinformatics/btu789
Stewart JJP. Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters. J Mol Model. 2013;19:1-32. doi:10.1007/s00894-012-1667-x
Stewart JJP. MOPAC2016, Stewart Computational Chemistry. MOPAC; 2016.
Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-2791. doi:10.1002/jcc.21256
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455-461. doi:10.1002/jcc.21334
Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem. 1985;28:849-857. doi:10.1021/jm00145a002
Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11:905-919. doi:10.1038/nprot.2016.051
Jaghoori MM, Bleijlevens B, Olabarriaga SD. 1001 ways to run AutoDock Vina for virtual screening. J Comput Aided Mol Des. 2016;30:237-249. doi:10.1007/s10822-016-9900-9
Gorgulla C, Boeszoermenyi A, Wang Z, et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020;580:663-668. doi:10.1038/s41586-020-2117-z
Craig IR, Essex JW, Spiegel K. Ensemble docking into multiple Crystallographically derived protein structures: an evaluation based on the statistical analysis of enrichments. J Chem Inf Model. 2010;50:511-524. doi:10.1021/ci900407c
Rao S, Sanschagrin PC, Greenwood JR, Repasky MP, Sherman W, Farid R. Improving database enrichment through ensemble docking. J Comput Aided Mol Des. 2008;22:621-627. doi:10.1007/s10822-008-9182-y
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3:935-949. doi:10.1038/nrd1549
Perola E, Walters WP, Charifson PS. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins. 2004;56:235-249. doi:10.1002/prot.20088
Allen WJ, Rizzo RC. Implementation of the Hungarian algorithm to account for ligand symmetry and similarity in structure-based design. J Chem Inf Model. 2014;54:518-529. doi:10.1021/ci400534h
Ballante F, Marshall GR. An automated strategy for binding-pose selection and docking assessment in structure-based drug design. J Chem Inf Model. 2016;56:54-72. doi:10.1021/acs.jcim.5b00603
Barril X, Morley SD. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem. 2005;48:4432-4443. doi:10.1021/jm048972v
Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol. 2004;337:209-225. doi:10.1016/j.jmb.2004.01.003
Webber W, Moffat A, Zobel J. A similarity measure for indefinite rankings. ACM Trans Inf Syst. 2010;28:1-38. doi:10.1145/1852102.1852106
Kendall MG. Rank Correlation Methods. Oxford University Press; 1990.